Výsledky vyhledávání - "Deepak L, Vardesh"

Autor: Deepak L, Vardesh, Sunil, Pandey, Hayley, Chen

Publikováno v: Australian Journal of General Practice. 51:347-349

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b593453ebe7df7667bf2db8a3fcb8752
https://doi.org/10.31128/ajgp-06-21-6033

Zobrazit plný text záznamu

Anti‐lipid therapy and risk factor management for triglyceridaemia‐induced acute pancreatitis

Autor: Peter J. Yuide, Renee Tabone, Justin Gundara, Deepak L Vardesh, Matthew J. Burstow, Terence C. Chua

Publikováno v: ANZ Journal of Surgery. 90:1997-2003

Background: Pancreatitis secondary to hypertriglyceridaemia is rare, accounting for less than 5% of pancreatitis presentations. We reviewed our institutional experience with triglyceridaemia induced acute pancreatitis to report the clinical presentat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39ea92ce8ac56b1c68cbe742d44faab9
https://doi.org/10.1111/ans.15829

Zobrazit plný text záznamu

Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost

Autor: Nicholas A Gray, P. R. Hollett, Rathika Krishnasamy, Deepak L Vardesh, Chris Anstey

Publikováno v: Nephrology. 16:688-696

Aim: The Australian Pharmaceutical Benefits Scheme (PBS) commenced cost subsidization for haemodialysis patients of sevelamer in December 2007, cinacalcet in July 2008 and lanthanum in May 2009. To determine the impact of PBS listing of these medicat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a75e4277f330a940cb0d6c50889603f6
https://doi.org/10.1111/j.1440-1797.2011.01482.x

Zobrazit plný text záznamu

The Slo-Niacin Trial: A Randomized Double-Blind Placebo-Controlled Cross-Over Trial of Extended Release Niacin for Phosphate Lowering in Haemodialysis Patients

Autor: Elizabeth Jarvis, Jeremy Frazier, Deepak L Vardesh, Padma Raman, Ken-Soon Tan

Publikováno v: Journal of Nephrology & Therapeutics.

Aim: Is once daily low dose extended release niacin effective at lowering phosphate? Background: Serum phosphate levels correlate with mortality in dialysis patients. Current phosphate binders often cause side-effects leading to poor compliance. Niac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f45659c5431028c160e1a75cbf707c86
https://doi.org/10.4172/2161-0959.1000157

Zobrazit plný text záznamu

Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost

Autor: Nicholas A, Gray, Rathika, Krishnasamy, Deepak L, Vardesh, Peter R, Hollett, Chris M, Anstey

Publikováno v: Nephrology (Carlton, Vic.). 16(8)

The Australian Pharmaceutical Benefits Scheme (PBS) commenced cost subsidization for haemodialysis patients of sevelamer in December 2007, cinacalcet in July 2008 and lanthanum in May 2009. To determine the impact of PBS listing of these medications,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b97c3a74bef251e4ba3452b4bfd52f09
https://pubmed.ncbi.nlm.nih.gov/21649793

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání